Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients

A. Salmaggi, C. Milanese, M. Eoli, L. La Mantia, A. Nespolo, A. Dufour

Research output: Contribution to journalArticlepeer-review

Abstract

15 patients with progressive Multiple Sclerosis (MS) were treated by an induction Cyclophosphamide (CFX) schedule followed by bimonthly boosters over one year. Of the 14 patients who completed the trial, only two displayed worsening of neurological status. Cerebrospinal fluid (CSF) total protein, IgG/Alb ratio and IgG index decreased at 6 months and were still low at the end of the treatment. Pretreatment percentages of PB CD8+ and CD4+CD45RA+ lymphocytes were lower in MS patients in comparison with healthy controls. However, no significant shifts occurred in percentage of PB CD4+, CD4+CD45RA+, CD4+CD45RA-, CD8+ lymphocytes of MS patients during immunosuppressive treatment. The lack of changes in the investigated immunological parameters contrasts with the good clinical response and the low rate of serious side effects during this treatment schedule.

Original languageEnglish
Pages (from-to)305-312
Number of pages8
JournalInternational Journal of Neuroscience
Volume76
Issue number3-4
DOIs
Publication statusPublished - 1994

Keywords

  • Cerebrospinal fluid
  • Cyclophosphamide
  • Multiple Sclerosis
  • T-cell subsets

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients'. Together they form a unique fingerprint.

Cite this